HomeAI · summaries
Storia in 3 fonti
Galderma Slumps After FDA Turns Down Botox Rival Relfydess
(Bloomberg) -- Galderma Group AG shares slumped the most in more than a year after the US Food and Drug Administration turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
- ·
swissinfo.ch
Galderma Slumps After FDA Turns Down Botox Rival Relfydess
(Bloomberg) -- Galderma Group AG shares slumped the most in more than a year after the US Food and Drug Administration turned down the Swiss dermatology firm’s rival Botox…
